



Dr. Reddy's Laboratories, Inc.
600 College Rd East, Suite 4000
Princeton, NJ. 08540

July 23, 2026

Notice Regarding Refunds to 340B Covered Entities for Purchases of Products

Dr. Reddy's Laboratories, Inc. ("Dr. Reddy's") recently completed a review of its 340B pricing records and identified overcharges affecting certain purchases made by Covered Entities under the 340B Drug Pricing Program. The overcharges resulted from adjustments following the determination of the actual 340B ceiling prices for following newly covered outpatient drugs:

For the period 4Q 2024:

NDC	Product Description
55111015910	Omeprazole DR Caps USP 40mg 1000s

For the periods 1Q and 2Q 2025:

NDC	Product Description
43598060330	Dasatanib Tablet 100mg 30s

For the periods 3Q and 4Q 2025:

NDC	Product Description
43598067611	Triamcinoacetone INJ USP 50mg/5ml 1s
55111039930	Lansoprazole DR Cap30mg 30s
75907016911	5-Fluorouracil Topical Cream 0.5% - 30g

Accordingly, Dr. Reddy's will proactively issue refunds via checks to 340B Covered Entities that purchased these products during the quarters identified above and are owed a refund of more than \$10 dollars in the aggregate for the impacted quarters.

Covered Entities who believe they may be entitled to a refund amount less than \$10.00 for purchases of the above listed products in the covered periods or have questions about refunds may contact Dr. Reddy's at kcherukumilli@drreddys.com with "Attn: 340B Refund" in the subject line to confirm any applicable amounts and to initiate the payment process.

Dr. Reddy's respectfully asks the Health Resources and Services Administration ("HRSA") to post this Notice on HRSA's public website to ensure transparency to all 340B Covered Entities.